Highest-materiality recent filing
Cardiff Oncology sues Nerviano Medical Sciences over onvansertib license inventorship dispute
Filed suit in SD California for injunctive relief and declaratory judgment it did not breach license agreement for onvansertib.
Cardiff Oncology reports Q1 cash $46.1M, FDA aligns on Phase 3 design for onvansertib
Cash and investments $46.1M at Q1 end; net cash used $12.3M, runway into Q1 2027.
Cardiff Oncology appoints permanent CEO, new CFO and COO; Muntner gets stock option inducement
Mani Mohindru promoted from interim to President & CEO; base salary $655K, $100K bonus plus 55% discretionary.
Cardiff Oncology finalizes separation agreements with ex-CEO and ex-CFO
Dr. Erlander to receive $635k salary over 12 months, $122k 2025 bonus, and 50% of 2026 target bonus pro-rated.
Cardiff Oncology furnishes Feb 2026 corporate presentation; no material news
Corporate slide presentation furnished as Exhibit 99.1 for investor meetings.
Phase 2 CRDF-004: ORR 72.2% vs 43.2% combined SoC; PFS HR 0.37 (p<0.05) for 30 mg onvansertib + FOLFIRI/bev in first-line RAS-mutated mCRC.
Cardiff Oncology CEO and CFO step down; onvansertib Phase 2 hits 72.2% ORR in mCRC
CEO Mark Erlander and CFO James Levine stepped down; Mani Mohindru named interim CEO, Brigitte Lindsay promoted to CAO.
Cardiff Oncology Q3 cash $60.6M; Phase 2 trial shows 19% ORR improvement in mCRC
Onvansertib 30mg cohort showed 19% improvement in confirmed ORR vs control in RAS-mutated mCRC Phase 2 trial.
Cardiff Oncology reports 49% confirmed ORR with onvansertib+SoC in Phase 2 mCRC trial; Q2 cash $71M
Confirmed ORR 49% (30mg onvansertib+SoC) vs 30% control in ITT population (N=110); early PFS trend favoring 30mg.
Cardiff Oncology stockholders approve all proposals at 2025 annual meeting
Seven director nominees elected, including CEO Mark Erlander, with between 20.4M and 21.2M votes each.
Cardiff Oncology appoints Dr. Roger Sidhu as CMO; to share CRDF-004 data on July 29
Dr. Fairooz Kabbinavar stepped down as CMO effective June 13, 2025; will remain as advisor.
On June 13, 2025, Dr. Fairooz Kabbinavar and Cardiff Oncology, Inc. (the “Company”) agreed that he would be stepping down from his position as Chief Medical Officer.
On June 17, 2025, the Company announced that it has appointed Dr. Roger Sidhu as its new Chief Medical Officer and entered into an employment agreement with Dr. Sidhu on June 16, 2025 (the “Sidhu Employment Agreement”).
Max materiality 0.90 · Median 0.60 · Most common event other_material